Learn how to anticipate, monitor, and manage PI3K/AKT therapy side effects in advanced HR-positive, HER2-negative breast cancer after CDK4/6 failure.
A Practical Approach to Toxicity Management With PI3K/AKT Pathway-Directed Therapy in HR+/HER2-Negative Advanced Breast Cancer
Explore how tissue biopsies and ctDNA blood tests reveal tumor genetics in metastatic breast cancer, with liquid biopsy offering easier, broader insights.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zanubrutinib Plus Rituximab Receives FDA Priority Review in Frontline MCL
3
How Will Pancreatic, Prostate, and Endometrial Cancer Care Change by 2031?
4
Signatera ctDNA Test Shows Clinical Utility in Head and Neck Cancer
5